These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26572230)

  • 1. Activation of MEK2 is sufficient to induce skin papilloma formation in transgenic zebrafish.
    Chou CM; Chen YC; Su S; Chen GD; Huang KY; Lien HW; Huang CJ; Cheng CH
    J Biomed Sci; 2015 Nov; 22():102. PubMed ID: 26572230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia.
    Scholl FA; Dumesic PA; Barragan DI; Harada K; Charron J; Khavari PA
    Cancer Res; 2009 May; 69(9):3772-8. PubMed ID: 19383924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive MEK1 activation rescues anthrax lethal toxin-induced vascular effects in vivo.
    Bolcome RE; Chan J
    Infect Immun; 2010 Dec; 78(12):5043-53. PubMed ID: 20855511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endosomal targeting of MEK2 requires RAF, MEK kinase activity and clathrin-dependent endocytosis.
    Galperin E; Sorkin A
    Traffic; 2008 Sep; 9(10):1776-90. PubMed ID: 18657070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
    Voisin L; Julien C; Duhamel S; Gopalbhai K; Claveau I; Saba-El-Leil MK; Rodrigue-Gervais IG; Gaboury L; Lamarre D; Basik M; Meloche S
    BMC Cancer; 2008 Nov; 8():337. PubMed ID: 19014680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
    Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
    Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
    Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M
    Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional redundancy of the kinases MEK1 and MEK2: Rescue of the Mek1 mutant phenotype by Mek2 knock-in reveals a protein threshold effect.
    Aoidi R; Maltais A; Charron J
    Sci Signal; 2016 Jan; 9(412):ra9. PubMed ID: 26814233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of MEK inhibitors on rat neural stem cell differentiation: Repressive roles of MEK2 in neurogenesis and induction of astrocytogenesis by PD98059.
    Lee HR; Lee J; Kim HJ
    Pharmacol Res; 2019 Nov; 149():104466. PubMed ID: 31562895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
    Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
    Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
    Zhou HM; Bolon I; Nichols A; Wohlwend A; Vassalli JD
    Cancer Res; 2001 Feb; 61(3):970-6. PubMed ID: 11221892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
    Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
    Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia.
    Scholl FA; Dumesic PA; Barragan DI; Harada K; Bissonauth V; Charron J; Khavari PA
    Dev Cell; 2007 Apr; 12(4):615-29. PubMed ID: 17419998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.
    Lee CS; Dykema KJ; Hawkins DM; Cherba DM; Webb CP; Furge KA; Duesbery NS
    PLoS One; 2011 Feb; 6(2):e17165. PubMed ID: 21365009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression.
    Allen SM; Florell SR; Hanks AN; Alexander A; Diedrich MJ; Altieri DC; Grossman D
    Cancer Res; 2003 Feb; 63(3):567-72. PubMed ID: 12566297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A full-length 3D structure for MAPK/ERK kinase 2 (MEK2).
    Liang H; Liu T; Chen F; Liu Z; Liu S
    Sci China Life Sci; 2011 Apr; 54(4):336-41. PubMed ID: 21509657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.
    Roy M; Li Z; Sacks DB
    Mol Cell Biol; 2005 Sep; 25(18):7940-52. PubMed ID: 16135787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.
    Kocieniewski P; Lipniacki T
    Phys Biol; 2013 Jun; 10(3):035006. PubMed ID: 23735655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mek1 and Mek2 functions in the formation of the blood placental barrier].
    Nadeau V; Bissonauth V; Charron J
    Med Sci (Paris); 2012 Apr; 28(4):409-15. PubMed ID: 22549869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.